Howard Gurney
1992–2025 年に発表
- 120
- 論文数
- 33,390
- 被引用数
- 60
- h 指数
- 111
- i10 指数
被引用数
引用元
国・地域
機関
分野
- Medicine81.6%
- Biochemistry, Genetics and Molecular Biology11.3%
- Immunology and Microbiology4.4%
- Engineering0.6%
- Mathematics0.4%
- Pharmacology, Toxicology and Pharmaceutics0.4%
- その他1.3%
トピック
- Cancer Immunotherapy and Biomarkers17.5%
- Renal cell carcinoma treatment7.4%
- Bladder and Urothelial Cancer Treatments5.5%
- Immunotherapy and Immune Responses3.8%
- Ferroptosis and cancer prognosis3.8%
- CAR-T cell therapy research3.1%
- その他58.9%
共著者
- Toni K. Choueiri44
- Thomas Powles36
- Robert J. Motzer35
- Camillo Porta25
- Yoshihiko Tomita23
- Bernard Escudier21
- Brian I. Rini19
- Elizabeth R. Plimack19
- Saby George19
- Frede Donskov18
- Mauricio Burotto18
- David F. McDermott17
- Jae‐Lyun Lee17
- Christian Kollmannsberger16
- Cristina Suárez16
- Daniel P. Petrylak16
- Cora N. Sternberg15
- Joaquim Bellmunt15
- Hans J. Hammers14
- Laurence Albigès14
- Jens Bedke13
- Se Hoon Park13
- Daniel Castellano12
- Nizar M. Tannir12
全論文
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 被引用: 5,890
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
著者: Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri - New England Journal of Medicine 2021 被引用: 1,761
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri - New England Journal of Medicine 2019 被引用: 2,550
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
著者: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 被引用: 3,390
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
著者: Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas - New England Journal of Medicine 2020 被引用: 1,479
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M. Burke, Gurjyot K. Doshi, Delphine Topart, Stéphane Oudard, Hans J. Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F. Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
著者: Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Peter Francis, George Wang, Daphne Wu, Brooke Diorio, Angela Lopez‐Gitlitz, Shahneen Sandhu, on behalf of the MAGNITUDE Principal Investigators, María Alejandra Álvarez, Gabriela Gatica, Martín Greco, Ernesto Korbenfeld, Esteban Metrebián, Jorge Salinas, Alejandro Salvatierra, Marcelo Tatangelo, Tom Ferguson, Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Guo Yonglian, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon ほか 141 名 - Journal of Clinical Oncology 2023 被引用: 319
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
著者: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 被引用: 1,010
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
著者: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 被引用: 263
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
著者: Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri - The Lancet Oncology 2022 被引用: 307
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
著者: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 被引用: 522
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
著者: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 被引用: 780
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
著者: K.N. Chi, Shahneen Sandhu, Matthew R. Smith, Gerhardt Attard, Marniza Saad, David Olmos, Elena Castro, Guilhem Roubaud, Andrea Juliana Gomes, Eric J. Small, Dana E. Rathkopf, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Karen Urtishak, A. del Corral, Peter Francis, W. Kim, Eleni Efstathiou - Annals of Oncology 2023 被引用: 199
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen-Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross‐Goupil, Tian Zhang, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stéphane Oudard, Delphine Topart, Hans J. Hammers, Hiroshi Kitamura, David F. McDermott, Adriano da Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles - New England Journal of Medicine 2024 被引用: 285
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
著者: Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas - Journal of Clinical Oncology 2023 被引用: 211
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
著者: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz ほか 133 名 - The Lancet Oncology 2022 被引用: 278
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
著者: Toni K. Choueiri, Robert J. Motzer, Brian I. Rini, John B.A.G. Haanen, Matthew T. Campbell, B. Venugopal, Christian Kollmannsberger, Gwénaëlle Gravis, Mamoru Uemura, J.L. Lee, Marc‐Oliver Grimm, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Sumanta K. Pal, J. Wang, Mariangela Mariani, S. Krishnaswami, Paul Cislo, A. Chudnovsky, Camilla Fowst, Bo Huang, Alessandra di Pietro, Laurence Albigès - Annals of Oncology 2020 被引用: 461
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
著者: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 被引用: 337
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
著者: Yves Fradet, Joaquim Bellmunt, David J. Vaughn, J L Lee, Lawrence Fong, Nicholas J. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, K. Nam, Tara L. Frenkl, Rodolfo F. Perini, Ronald de Wit, Dean F. Bajorin - Annals of Oncology 2019 被引用: 488
- Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
著者: Matthew R Smith, Matthew R Smith, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Olof Ståhl, David Olmos, Daniel C Danila, Gary E Mason, Byron M Espina, Xin Zhao, Karen A Urtishak, Peter Francis, Angela Lopez-Gitlitz, Karim Fizazi, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, Thomas Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D'Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich ほか 34 名 - The Lancet Oncology 2022 被引用: 186
- Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
著者: Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler ほか 141 名 - Journal of Clinical Oncology 2024 被引用: 158
- Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
著者: Laurence Albigès, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, Rodolfo F. Perini, Manish Sharma, Xiang Peng, Chung‐Han Lee - The Lancet Oncology 2023 被引用: 149
